News
GI Bleeding Lower With Apixaban vs Other DOACs in A-Fib
No substantial differences seen for other outcomes or for other direct oral anticoagulant comparisons
Your search for apixaban returned 18 results
News
Apixaban Bests Rivaroxaban in “Emulated” Trial of Patients With Afib and VHD
Apixaban and rivaroxaban are both factor Xa inhibitors.
News
Apixaban Noninferior to Enoxaparin for Postoperative VTE Prophylaxis
Fewer compliance events seen with apixaban versus enoxaparin for extended-duration VTE prophylaxis after abdominopelvic oncologic surgery
News
Apixaban Tied to Lower Risk for Recurrent VTE in Dialysis Population
Apixaban is a direct oral anticoagulant that relies less on kidney excretion.
News
Rates of Recurrent VTE Compared for Apixaban, Rivaroxaban
Among new users, rates of recurrent venous thromboembolism, GI and intracranial bleeding lower with apixaban than rivaroxaban
News
Noncompliance to Apixaban for A-Fib Due to Many Factors
Improved communication with patients about cost, bleeding, and monitoring may increase compliance
News
Rates of Adverse Events Lower With Apixaban for A-Fib in Older Adults
Apixaban the only direct oral anticoagulant linked to lower adverse event rates than warfarin for patients with atrial fibrillation across frailty levels
News
Network Meta-Analysis Compares DOACs to LMWH for Cancer-Linked Thrombosis
Apixaban dominated enoxaparin and edoxaban; rivaroxaban was slightly more effective than apixaban
Drugs in the Pipeline
Novel Factor XI Inhibitor Fast Tracked for Thrombosis Associated With Cancer
Abelacimab is a highly selective, fully human monoclonal antibody designed to inhibit both factor XI and its activated form, factor XIa.
News
DOACs Cut Recurrent VTE in Adults With Cancer-Related Thrombosis
Direct oral anticoagulants reduce recurrent VTE events by 41 percent, with no significant increase in major bleeding, compared to dalteparin
